Most Clicked DiabetesPro SmartBrief Stories

1. HHS announces $212M to boost chronic disease prevention

DiabetesPro SmartBrief | Sep 29, 2014

HHS is set to award about $212 million in grants to bolster chronic disease prevention in the U.S. Some of the grants are targeted at improving nutrition and physical activity, reducing tobacco use and educating consumers on health and wellness. Healio (free registration) (09/26)

2. Study rejects link between DPP-4 inhibitors, pancreatic cancer risk in diabetes

DiabetesPro SmartBrief | Sep 26, 2014

An analysis of Medicare claims data found that use of dipeptidyl-peptidase-4 inhibitors for glycemic control does not appear to increase the odds of short-term pancreatic cancer risk compared with sulfonylureas and thiazolidinediones. The findings are reported in the journal Diabetes, Obesity and Metabolism. (09/22)

3. Omarigliptin, sitagliptin show comparable diabetes outcomes

DiabetesPro SmartBrief | Sep 23, 2014

Data presented at the European Association for the Study of Diabetes meeting showed type 2 diabetes patients who took once-weekly omarigliptin attained better A1C, postprandial glucose and fasting plasma glucose levels than those in the placebo cohort. Researchers found patients in the omarigliptin arm exhibited improvements comparable with those who took once-daily sitagliptin. Healio (free registration) (09/19)

4. Canagliflozin yields weight loss, study finds

DiabetesPro SmartBrief | Sep 26, 2014

Using either canagliflozin or glimepiride as an add-on to metformin treatment resulted in glycemic control improvements in patients with type 2 diabetes, a study in Diabetes Care indicated. However, canagliflozin therapy was tied to weight loss and fewer hypoglycemic events in patients. Medscape (free registration) (09/25)

5. Better diabetes outcomes seen with degludec/liraglutide combo

DiabetesPro SmartBrief | Sep 24, 2014

Data presented at the European Association for the Study of Diabetes meeting revealed a fixed-dose insulin degludec/liraglutide combination resulted in greater blood glucose control in type 2 diabetes patients compared with either monotherapy. Healio (free registration) (09/23)

6. Roche's glucose monitor with insulin calculator wins FDA nod

DiabetesPro SmartBrief | Sep 23, 2014

The FDA has cleared Roche to market its Accu-Chek Aviva Expert device, which is said to be the first diabetes-management system that merges a blood-glucose monitor and an insulin calculator into a single unit. The prescription device is offered only to patients who can self-administer insulin injections. (Boston) (09/18)

7. Treatment combo boosts A1C control in type 2 diabetes

DiabetesPro SmartBrief | Sep 23, 2014

Type 2 diabetes patients who took a fixed-dose empagliflozin/linagliptin combination attained better A1C at 52 weeks compared with those on either monotherapy, researchers reported at the European Association for the Study of Diabetes meeting. Data also showed the combination treatment resulted in improved body weight and systolic blood pressure in patients. The fixed-dose therapy showed similar benefits for both metformin-treated and drug-naive patients, researchers said. Healio (free registration) (09/22)

8. U.S. sees decline in new diabetes cases, CDC finds

DiabetesPro SmartBrief | Sep 24, 2014

CDC officials found the number of new diabetes cases in the U.S. increased from 3.2 per 1,000 people in 1990 to 8.8 per 1,000 people in 2008, but declined to 7.1 per 1,000 people in 2012. However, researchers noted a persistent increase among Hispanics, blacks and those with lower education levels. The findings were published in the Journal of the American Medical Association. Reuters (09/23)

9. Study examines effects of glucose control on type 2 diabetes

DiabetesPro SmartBrief | Sep 24, 2014

A study of people with type 2 diabetes found that intensive blood pressure reduction was better for the long-term prevention of heart attack and stroke than intensive blood glucose control. Blood glucose control did have a long-term effect on preventing patients from developing kidney disease, researchers reported in the New England Journal of Medicine. HealthDay News (09/19)

10. Work type, duration may influence diabetes risk

DiabetesPro SmartBrief | Sep 25, 2014

People who spent more than 55 hours per week at manual or "low socioeconomic status" jobs had a 30% increased risk of diabetes than those who worked 35 to 40 hours per week, according to a study in The Lancet Diabetes & Endocrinology. HealthDay News (09/25)

Sign up for DiabetesPro SmartBrief

Designed specifically for health care professionals, DiabetesPro SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news, trends, and technology updates that matter most to health care professionals. Learn more